The two companies have entered into a collaboration agreement to develop advanced end-to-end workflows for the preparation, characterization and monitoring of novel and complex biotherapeutics using liquid chromatography-mass spectrometry (LC-MS).
The collaborative partnership aims to develop advanced end-to-end methods for the analysis of novel and complex biotherapeutics to meet the increasing demands for high throughput, rapid and simplified analytical workflows. Bringing together Genovis enzyme-based sample preparation and analysis techniques with Thermo Fisher’s LC-MS technology, the collaboration will develop robust automation-ready solutions and chromatography-based workflows for the streamlined analysis of biotherapeutics.
More automated analytical workflows
Scientist at Genovis will work together with expertise from Thermo Fisher’s Global Customer Solution Centers will also help to determine optimal hardware/software configurations and suitable consumables for critical quality attribute (CQA) analysis of biotherapeutics during research and development.
“We are excited to continue our clear ambition towards more automated analytical workflows together with Thermo Fisher Scientific, a renowned world leader in serving science with instrumentation, technologies and consumables. Through this collaboration we will be able to develop new products and workflows on world-class instrumentation together with experts from the European Biopharma Customer Solutions Centre at Thermo Fisher, with the goal to serve the customers of both companies with innovations for the ever-growing analytical needs within the biopharma industry,” says Fredrik Olsson CEO at Genovis.
Photo of Fredrik Olsson: Genovis